AU2001261832A1 - Methods for inhibiting proliferation and inducing apoptosis in cancer cells - Google Patents

Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Info

Publication number
AU2001261832A1
AU2001261832A1 AU2001261832A AU6183201A AU2001261832A1 AU 2001261832 A1 AU2001261832 A1 AU 2001261832A1 AU 2001261832 A AU2001261832 A AU 2001261832A AU 6183201 A AU6183201 A AU 6183201A AU 2001261832 A1 AU2001261832 A1 AU 2001261832A1
Authority
AU
Australia
Prior art keywords
leukotriene
alkyl
compound
ethyl
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261832A
Other languages
English (en)
Inventor
Thomas E. Adrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Original Assignee
Creighton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creighton University filed Critical Creighton University
Publication of AU2001261832A1 publication Critical patent/AU2001261832A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001261832A 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells Abandoned AU2001261832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US60219344 2000-05-09
PCT/US2001/040697 WO2001085166A1 (fr) 2000-05-09 2001-05-08 Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses

Publications (1)

Publication Number Publication Date
AU2001261832A1 true AU2001261832A1 (en) 2001-11-20

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261832A Abandoned AU2001261832A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Country Status (11)

Country Link
EP (1) EP1326605A4 (fr)
JP (1) JP2003532675A (fr)
KR (1) KR20030019372A (fr)
CN (1) CN1237968C (fr)
AU (1) AU2001261832A1 (fr)
BR (1) BR0110473A (fr)
CA (1) CA2408622A1 (fr)
MX (1) MXPA02010974A (fr)
NO (1) NO20025343L (fr)
NZ (1) NZ522387A (fr)
WO (1) WO2001085166A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (fr) * 2007-09-10 2009-03-11 Universite Libre De Bruxelles Récepteur de la lipocaline soluble liant le leukotriène B4 issu de Ixodes ricinus
EA023067B1 (ru) 2012-01-10 2016-04-29 Эли Лилли Энд Компани Соединение, представляющее собой антагонист лейкотриена b
CN105307682B (zh) 2013-04-22 2020-10-02 株式会社栃木临床病理研究所 抗肿瘤剂
SI3083564T1 (sl) 2013-12-20 2018-10-30 Novartis Ag Derivati heteroarilbutanojske kisline kot inhibitorji LTA4H

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
EP0777472A2 (fr) * 1994-08-31 1997-06-11 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques aux fins du traitement de cancer
PL355172A1 (en) * 1999-11-11 2004-04-05 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2003513914A (ja) * 1999-11-11 2003-04-15 イーライ・リリー・アンド・カンパニー 癌の処置のための腫瘍崩壊薬の組み合わせ

Also Published As

Publication number Publication date
NO20025343D0 (no) 2002-11-07
EP1326605A4 (fr) 2004-03-17
EP1326605A1 (fr) 2003-07-16
KR20030019372A (ko) 2003-03-06
JP2003532675A (ja) 2003-11-05
CN1237968C (zh) 2006-01-25
CA2408622A1 (fr) 2001-11-15
NO20025343L (no) 2003-01-09
CN1429111A (zh) 2003-07-09
NZ522387A (en) 2003-09-26
BR0110473A (pt) 2003-04-01
MXPA02010974A (es) 2004-09-06
WO2001085166A1 (fr) 2001-11-15

Similar Documents

Publication Publication Date Title
Pizer et al. Increased fatty acid synthase as a therapeutic target in androgen‐independent prostate cancer progression
Chen et al. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis
Stuckler et al. RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non–Small Cell Lung Cancer
RU2389507C2 (ru) Лечение рака
US10420814B2 (en) Composition for treating cancer stem cells
KR102361078B1 (ko) 말산-아스파르트산 왕복수송 억제제 및 카르니틴 아실카르니틴 운반자 수송 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
US11046647B2 (en) Activators of the unfolded protein response
JP2003513920A (ja) 細胞内マロニルＣｏＡレベルの増加による癌の治療
Gu et al. Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation
JP4667873B2 (ja) α５β１およびその細胞生存経路を調節する能力
WO2020234454A1 (fr) Traitement combiné contre le cancer ciblant le métabolisme énergétique et le ph intracellulaire
AU2001261832A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
US20040053962A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
US6054437A (en) Method for inducing death of neoplastic cells using piperazine derivatives
US9895363B2 (en) Methods for modulating function of proliferating cell nuclear antigen (PCNA) and treating cancer with PCNA-targeting compounds
US20130022612A1 (en) Methods and compositions for malaria prophylaxis
WO2017103625A1 (fr) Traitement contre le cancer
Kamei et al. Ketoprofen in topical formulation decreases the matrix metalloproteinase‐2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma
Liu et al. A novel small molecular STAT3 inhibitor, 5Br-6b, induces apoptosis and inhibits migration in colorectal cancer cells
WO2019098288A1 (fr) Agent antitumoral et agent de formulation
CA2436536C (fr) Methodes permettant d'induire l'apoptose et d'inhiber la proliferation de cellules cancereuses
WO2022089602A1 (fr) Nouvelle cible pour le diagnostic et le traitement du cancer du poumon à petites cellules résistant aux médicaments de chimiothérapie et son application
CN101022796A (zh) 抑制肿瘤转移的方法
JP2008230977A (ja) ニチジンを成分とする抗癌剤、および該抗癌剤の感受性増強剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application